As minocycline has previously been shown to improve attention deficits in human patients with schizophrenia (Liu et al. 2014), these results further warrant the refinement of Map2k7+/− mice as a model of attentional and possibly other cognitive impairments because the ability to maintain and focus attention enhances performance in other cognitive domains. Here, MAP2K7 is linked to schizophrenia.